Pfizer Pharmaceuticals Group
Regulatory Affairs Division
Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755
Tel 212 573 3412 Fax 212 857 3558
Email clarkr3@pfizer.com

Pfizer Pharmaceuticals

0282 '99 APR 26 NO:32

April 23, 1999

Robert B. Clark
Director
Team Leader
Regulatory Affairs

Dockets Management Branch (HFA-305)
Food and Drug Administration
Department of Health and Human Services
Room 1061
5630 Fishers Lane
Rockville, MD 20852

PEDIATRIC PRIORITY LIST

CITIZEN PETITION

The undersigned submits this petition pursuant to 21 C.F.R. §10.30, pursuant to Food and Drug Administration ("FDA") Docket No. 98N-0056, "List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population" (May 20, 1998), and pursuant to paragraph V(c) of FDA, "Guidance for Industry: Qualifying for Pediatric Exclusivity under Section 505A of the Federal Food, Drug and Cosmetic Act" (June 1998), under Section 505A of the Food, Drug and Cosmetic Act, 21 USC §355a, to request the Commissioner of Food and Drugs to add alatrofloxacin to the Priority List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population, as published by FDA under Docket No. 98N-0056 ("Priority List").

A. Action Requested

The undersigned requests that the Commissioner add alatrofloxacin to the Priority List.

B. Statement of Grounds

Trovan® is a synthetic broad-spectrum antibacterial agent developed and marketed by Pfizer. It is approved in tablet formulation as trovafloxacin mesylate (NDA # 20-759), and in IV formulation as alatrofloxacin mesylate (NDA # 20-760). Alatrofloxacin mesylate is a prodrug of trovafloxacin mesylate.

99P-1172

CP1

Trovan was approved on December 18, 1997, with indications for the treatment of a variety of infections caused by the strains of the microorganisms set forth in the product's prescribing information. Because many of these infections occur in pediatric patients, additional information on both trovafloxacin mesylate and alatrofloxacin mesylate may produce health benefits in the pediatric population.

FDA included trovafloxacin mesylate in the Priority List but omitted alatrofloxacin mesylate. This omission should be corrected, so that a Written Request for pediatric studies under §111(c) of the Food and Drug Administration Modernization Act of 1997, 21 USC § 355a (c), may include alatrofloxacin mesylate, as well as trovafloxacin mesylate.

C. Environmental Impact

The subject matter of this petition is not within any of the categories of action for which an environmental assessment is required pursuant to 21 C.F.R. §25.22, and is exempt pursuant to 21 C.F.R. §25.30(a), in that it is concerned with routine FDA administrative and management activities.

D. Economic Impact

Not requested.

E. Certification

The undersigned certifies that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner which are unfavorable to the petition.

Respectfully submitted,

PFIZER INC

By Robert B Clark

Robert B. Clark
Director/Team Leader
235 East 42nd Street
New York, NY 10017
(212) 573-3412

cc: Dr. Mark Goldberger, Director (HFD-590)
Ms. Rene Kimsey, Project Manager (HFD-590)

The World On

Pfizer Inc
235 East 42nd Street
New York, NY 10017-5755

pfizer

Dockets Management Branch (HFA-305)
Food and Drug Administration
Health and Human Services